PPARA and metabolic syndrome: The most notable age-reducing drugs (Figure 3c) include ouabain, a cardiac glycoside with established senolytic properties (=−5.74, P = 8.59 × 10−6, score = 123), the mTOR inhibitor rapamycin (=−7.50, P = 9.83 × 10−4, score = 105), and fenofibrate, a PPARα agonist used clinically for dyslipidemia (=−12.57, P = 1.04 × 10−4, score = 111).